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Abstract
Diabetic foot syndrome is a significant complication of diabe-
tes. Diagnostic imaging is a crucial factor determining surgical 
decision and extent of surgical intervention. At present the 
gold standard is MRI scanning, whilst the role of bone scan-
ning is decreasing, although in some cases it brings valuable 
information. In particular, in early stages of osteitis and Charcot 
neuro-osteoarthropathy, radionuclide imaging may be superior 
to MRI. Additionally, a significant contribution of inflammation-
-targeted scintigraphy should be noted. Probably the role of PET 
scanning will grow, although its high cost and low availability 
may be a limiting factor. In every case, vascular status should 
be determined, at least with Doppler ultrasound, with following 
conventional angiography or MR angiography. 
Key words: diabetic foot, radionuclide imaging, SPECT, 
PET, radiography, CT, MRI, Charcot neuro-osteoarthropathy 
Nuclear Med Rev 2010; 13, 1: 18–22
Introduction
Diabetes mellitus is a growing global epidemic of the twen-
ty-first century. According to the WHO, the number of patients with 
diabetes type II will rise from 132 million in 1997 to 220 million in 
2010, 250 million in 2020, and 300 million in 2025. One of the major 
debilitating complications of diabetes is diabetic foot, including the 
ulcerations and deformations of the foot with the protracted course 
and impaired healing. Diabetic foot ulcers and infections are com-
mon and incur substantial economic problems for society, patients, 
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and families. Usually the ulcerations of diabetic foot are the result 
of wrongly chosen shoes, small wounds caused by small objects in 
shoes, or thermal injury. Sometimes the patients are not aware of 
the wound, due to impaired feeling of pain, touch, and vibration; 
this may result in secondary infection of the wound, threatening 
foot amputation. The treatment of diabetic foot is difficult, and the 
history of treatment methods is rather sad and unfinished. There 
is no evidence that surgical debridement of the infected bone 
is routinely necessary. Culture and sensitivity of isolates from 
bone biopsy may assist in selecting properly targeted antibiotic 
regimens, but empirical regimens should include agents active 
against staphylococci, administered either intravenously or orally 
(with a highly bio-available agent). There are no data to support 
the superiority of any particular route of delivery of systemic anti-
biotics, or to give an indication of the optimal duration of antibiotic 
therapy [1]. 
In practice, three types of diabetic foot may be distinguished: 
s.c. vascular foot linked with microangiopathy and macroangio-
pathy, s.c neuropathic foot, and neuro-ischaemic foot mixed form.
Medical imaging of the diabetic foot entails a variety of imaging 
modalities. The diagnostic evaluation often includes a gamut of 
studies that include conventional radiography, CT, nuclear medi-
cine scintigraphy, MRI, ultrasonography, and a newcomer, positron 
emission tomography combined with CT and leukocyte labelling. 
There is not yet “one best test” for sorting out the diagnostic dilem-
mas that are commonly encountered. Confirmation or exclusion 
of the frequent diagnosis of osteomyelitis often requires multiple 
studies, which are complementary to one another [2]. This paper 
reviews the advantages and disadvantages of particular meth-
ods with emphasis on the particular forms of diabetic foot. 
Clinical factors 
One of the most important epidemiological parameters of 
diabetic foot is the number of lower limb amputations. Half of them 
are performed in diabetic patients. Most of them do not return to 
previous fitness, which may cause inability to work, and some-
times also to incapability of independent existence. The loss of 
lower limb significantly increases the risk of amputation of the 
other limb [3]. In patients with diabetic foot, neuropathy as a sole 
aetiological factor is seen in 62% of patients, microangiopathy 
without neuropathy in 13% of patients, and both factors in 25% of 
diabetic patients. In the western world the morbidity of diabetic foot 
is around 2%, and the frequency of amputations below the knee 
is 2 per 1000 cases. Risk factors are: age, sex and social status, 
smoking, alcohol abuse, and concomitant arterial hypertension, 
as well as some emotional factors, e.g. depression [4]. 
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Neuroarthropathy of the foot 
(Charcot’s neuroarthropathy) 
This is a distinct form of diabetic foot, involving bone and 
joints. It starts with neuropathy, the loss of feeling of pain, and 
abnormal mechanics of the foot [3]. The autonomic nervous sys-
tem neuropathy impairs the blood supply of the foot bones and 
joins. The clinical symptoms are foot oedema, skin rash, and foot 
deformation. The bones become fragmented, which may lead to 
the foot becoming a “skin sack” filled with bone fragments, with 
the threat of foot amputation [5]. 
Imaging of diabetic foot
Diagnostic imaging of diabetic foot should enable the dia-
betologist and surgeon to determine whether osteitis is present 
or not, and if so — what should be the extent of planned sur-
gery. One another important role is detecting and assessing 
early stages of diabetic neuroarthropathy. Lastly, radiological 
procedures play a significant role in assessing arteries before 
angioplasty. This is not an easy job. One of the most challeng-
ing tasks for the radiologist is differential diagnostics of infec-
tious changes and non-infectious neuroarthropathy, which may 
be nearly impossible [6].
Plain radiograms
Bone X-ray is widely available and inexpensive.  Plain radio-
grams are a good initial screening tool in diabetic osteomyelitis; 
however, their sensitivity is poor. Sensitivity of bone X-ray in diabetic 
foot is estimated between 43% and 75%, and specificity between 
75% and 83% [7]. Whilst interpreting bone X-rays, attention must 
be paid to bone deformations, osteolytic foci, and joint changes. 
Regretfully, plain X-ray is usually insufficiently sensitive in early 
osteitis, as well as in early osteoarthropathy, when bones are not 
deformed or fragmented, and so serial radiographs are necessary 
[4]. A relatively rare but characteristic finding is calcification of the 
foot dorsal artery in Mönckeberg’s sclerosis [8]. 
Sometimes X-ray densitometry may be useful in Charcot’s os-
teoarthropathy, to show regional mineral density variations. In 
numerous fractures mineral density is low, but at bone displace-
ments bone calcification remains normal [9].  
Computed tomography
In dubious cases bone biopsy is indicated. MRI also has a high 
potential for diagnosing deep abscesses, tendon ruptures, and 
septic exudate in joint cavities [10]. 
In Charcot’s osteoarthropathy, MRI shows bone and cartilage 
lesions (bone oedema, occult fractures, joint exudation) as early 
as in stage 0, when plain X-ray is normal; in the next stages: 
I (bone destruction), II (bone reunion), III (bone remodelling), the 
results are even better. 
MR angiography is useful in the assessment of blood outflow, 
particularly in peripheral artery occlusion. Contrary to conventional 
X-ray, MR angiography does not show calcification in the arteries [4]. 
According to two meta-analyses, MRI is the best diagnostic 
tool in diabetic foot imaging [11, 12]. Kapoor et al. analysed 16 
papers comparing different diagnostic tools and their diagnostic 
odds ratios (DOR) and obtained the following results: MRI sen-
sitivity and specificity 90%, DOR compared to radionuclide stu-
dies 149.9 vs. 3.6 (7 communications), plain radiography 81.3 vs. 
3.3 (9 communications), and scintigraphy of inflammation 120 vs. 
3.4 (4 communications). This analysis was supported by interesting 
economic data. In 2006 in the USA, costs were as follows: $288 for 
three-phase bone scintigraphy, $416 for limb MRI without contrast, 
and $451 for limb MRI contrast imaging. The authors postulate that 
due to the small  difference in cost and better MRI sensitivity, MRI 
is more cost-effective, with the exemption of patients with initially 
low disease probability [11].  
Similar conclusions were drawn by the American College of 
Radiologists Study Group in 2008 [13]. The authors agreed that 
in soft tissue oedema, skin ulcerations and suspicion of osteitis, 
MRI scanning with or without contrast is the imaging modality of 
choice. Also, in diabetic foot without ulceration, MRI is the preferred 
tool, with granulocyte-labelled scintigraphy as a second choice if 
contra-indications to MRI scanning exist.  
Perhaps a useful compromise would be hybrid PET/MRI scan-
ning, which has proven to be useful in many fields of pathology. CT, 
however, has numerous limitations, including the high dose of the 
ionising radiation absorbed. MRI scanning provides an excellent 
imaging contrast; it also enables NMR spectroscopy and functional 
imaging to be performed. Developing a PET/MRI device took at 
least 15 years. The crucial technical problem was the limitation 
of scintillation flash transfer through the high magnetic field [14]. 
This was overcome by utilising avalanche photodiodes (APDs) for 
gamma ray detection, as well as applying lutetium orthosilicate 
crystal detectors, which enabled the development of PET scan-
ners insensitive to magnetic fields [15].
A separate issue is the utility of magnetic resonance angiogra-
phy (MRA). Sometimes vascular changes invisible in conventional 
angiography are better seen in MRA, indicating the vessels for 
revascularisation [16]. 
Ultrasonographic and vascular examinations 
The risk of vascular changes is four-fold higher in diabetic 
patients than in patients without diabetes. Changes progress more 
aggressively in diabetic patients with a five-fold higher prob-
ability of critical ischaemia. Early diagnosis enables surgical or 
radiological intervention and revascularisation in 80% of patients. 
A non-invasive alternative is thrombolytic treatment [17].  
Doppler ultrasound visualises the patency of vessels and 
the direction of blood flow, detecting the critically narrowed ves-
sels without utilising conventional angiography [4].  This is im-
portant as patients with purely neuropathic forms of diabetic foot 
have much better prognosis than those with its ischaemic or mixed 
form do. Essentially, diabetic foot with and without peripheral 
artery disease are two distinct diseases with very different prog-
nosis and therapy, with strong emphasis on revascularisation in 
the latter form [18].  
Peripheral artery angioplasty (PTA) significantly decreases the 
number of amputations [19]. Arterial reconstruction provides excel-
lent long-term results with regard to amputation-free survival and 
limb salvage. It should be considered in every diabetic patient 
with extensive soft tissue deficits before amputation is performed 
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[20]. The starting point of this management is of course clinical 
assessment and Doppler ultrasound, but for precise delineation 
of vascular changes and reconstructive surgery planning it is ne-
cessary to perform conventional angiography or MRA. The basic 
angiological intervention is by-pass surgery or femoral endarterec-
tomy [21]. Angiological interventions much improve prognosis of 
foot healing, although angiography is not always a predictive factor 
[22]. Until recent times the gold standard was digital subtraction 
angiography (DSA); today 3D magnetic resonance angiogra-
phy is preferred because in most patients with diabetic foot, 
arterio-venous shunts occur and 3D imaging facilitates planning 
of reconstructive surgery [23]. Also, it seems that ultrasonography 
is partially able to replace angiography as the first choice test, 
selecting a group of patients for angiography with simultane-
ous angioplasty [24]. Therefore, a thorough preoperative vascular 
evaluation should be performed before the initiation of any lower 
extremity surgical intervention, particularly in situations of diabetic 
foot reconstruction with compromised blood flow [25]. Additionally, 
on ultrasound, the atrophy of intrinsic foot muscles determined at 
ultrasonography is directly related to foot muscle volume deter-
mined by MRI and to various measures of diabetic neuropathy. 
Ultrasonography seems to be useful for the detection of foot 
muscle atrophy in diabetes [25]. 
In contrast, in diabetic foot, assessment thermography and 
thermometry definitely failed. Medical applications of thermogra-
phy date back to the 1950s, with some progress of this method 
in cardiosurgery, angiology, and even ear/nose/throat (ENT) dis-
eases and dentistry, but still its sensitivity and specificity is quite 
low, result dispersion is high, and in diagnosing diabetic foot it 
has practically no application [27], although some authors still 
advocate its use [28].  
Conventional radionuclide imaging 
Early reports on scintigraphic imaging of diabetic foot date 
from about thirty years ago [29]. Today its position is diversified. 
The role of static and three-phase bone scan is decreasing, and 
the role of inflammation scintigraphy and PET increasing. Probably 
there is no “one-best-test” in radionuclide diabetic foot imaging, 
and those existing are complimentary [30]. Some authors believe 
that MRI is the method of choice and the others only have an aux-
iliary character [13]. The value of bone scintigraphy in the diabetic 
foot, even as a screening test, is questionable [31]. 
The most commonly applied method is three-phase bone 
scintigraphy utilising 99m-technetium phosphonates (MDP, EHDP, 
IDP, and others), followed by inflammation scintigraphy, and, rarely, 
bone marrow scintigraphy [32]. 
Muscle perfusion scintigraphy utilising 99m-Tc-MIBI or thal-
lium-201 did not gain wider acceptance [33] although it may be 
a promising method in assessing muscle-skin graft healing in 
diabetic foot reconstructive surgery [34].   
The main disadvantage of three-phase bone scintigraphy 
is unspecific bone radiotracer uptake secondary to foot degenera-
tive changes. “Hot” spots in feet, particularly of the first digit, are 
a frequent artefact of bone scintigraphy in patients without diabe-
tes. Sometimes performing a fourth phase scanning 24 hours post 
tracer injection may be helpful; the same concerns granulocyte-la-
belled scanning [35]. On the other hand, no significant difference 
in the amputation rate for patients with confirmatory, indeterminate, 
or nonconfirmatory three-phase bone scans for osteomyelitis (36%, 
37%, and 50%, respectively) (P > 0.5) was found. Therefore, the 
authors conclude that the ultimate treatment decision should be 
based on clinical indicators of the presence of uncontrolled infec-
tion or gangrene rather than on bone scan findings [36]. 
Inflammation scintigraphy may be performed utilising radio-
labelled granulocytes, radiolabelled polyclonal immunoglobulin, 
anti-granulocyte antibodies, or gallium-67. The best results are 
obtained utilising radiolabelled antibodies with sensitivity rang-
ing between 72–100% and specificity between 72–98%. Some 
authors advocate performing dual scintigraphy: three-phase bone 
scintigraphy and granulocyte-radiolabelled scintigraphy, with the 
assumption that positive result of both scans means osteitis, 
and that positive granulocyte scanning only indicates soft-tissue 
involvement [37]. Hybrid SPECT/CT scanning does not signifi-
cantly contribute to the evaluation of patients with negative scan 
results [38]. As the labelled leukocytes accumulate in uninfected 
neuropathic joints, bone marrow scintigraphy may be needed 
to determine whether infection is present [32]. In some cases, 
high-resolution scintigraphy (HRS) with mini-gamma camera and 
99mTc [HMPAO]-labelled leukocyte is able to diagnose early os-
teitis of diabetic foot and to guide diabetic foot surgery [39]. The 
position of gallium-67 scintigraphy is uncertain; the sensitivity of 
gallium-67 SPECT scanning is estimated at 67–70% with a spe-
cificity of 92% [7]. Technetium-99m radiolabelled ciprofloxacin 
has a relatively high sensitivity (86%), but care must be taken in 
cases of fastidious organisms and ciprofloxacin-resistant bacterial 
flora in which false results may be obtained (86%) [40]. Theoreti-
cally good results were obtained with radiolabelled dextran, but 
this technique did not gain popularity [41]. 
Positron emission tomography (PET)
PET/CT is also a promising technique, in the assessment 
of the muscular and skeletal system, in detecting inflammation 
sites [42]. The main target of PET is oncology and to a lesser 
extent cardiology and neurology; detecting inflammation currently 
represents around 1% of PET application. They comprise osteitis, 
complications of endoprostheses and bone grafting, pyrexia of 
unknown origin, immunodeficiency syndromes, including AIDS, in-
fections and fistulae of vascular grafting, and diabetic foot [42, 43]. 
PET applications in diabetic foot date back to the beginning of 
the present decade [44]. PET scanning is performed today almost 
exclusively with hybrid PET/CT cameras, and in recent years also 
PET/MRI with a significant improvement of diagnostic precision. 
Co-registration of PET with high-resolution anatomic CT imaging 
modalities may solve some clinical problems of diabetic foot. Small 
variations in limb positioning between separate studies may lead, 
however, to faulty localization of infectious foci, in particular where 
different structures are close to each other. Based on these initial 
results, hybrid PET/CT, combining 18-F-FDG assessment of infec-
tion and CT structural data of the skeleton, is likely to be a better, 
more accurate, and certainly simpler procedure for diagnosing 
osteomyelitis in the diabetic foot patient population [45]. 
Opinions regarding the use of PET in diabetic foot are diversi-
fied. Keidar et al. underline the high usefulness of PET/CT in dis-
criminating bone and soft tissue infection [45], whereas Schwegler 
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et al. in the material of 20 diabetic foot patients without suspicion 
of osteitis concluded that MRI was superior to 18F-FDG-PET and 
99m-Tc monoclonal antibodies [46]. PET may play an important 
role in the diagnosis of Charcot’s osteoarthropathy. PET shows the 
foci of bone remodelling both in visual analysis and SUV calcula-
tions. The differentiation between Charcot’s neuroarthropathy and 
florid osteomyelitis provides the surgeon with important additional 
information that often is unavailable from MRI [43, 47].  
There are practical problems of PET imaging related to hyper-
glycaemia, which is important when we analyse the diabetic foot 
patient population. The effect of hyperglycaemia on 18F-FDG-PET 
sensitivity is a controversial issue [48]. Some data suggest that 
elevated blood glucose levels may not impair 18F-FDG uptake in 
infection [49]. In a study of Keidar et al., although elevated glucose 
serum values were found in half the present study population at 
the time of 18F-FDG injection, this did not lead to false-negative 
studies. There was no relationship between the glycaemic state 
and the presence or absence of abnormal 18F-FDG uptake in the 
present study [45].  
Conclusions 
An interesting result shows the mentioned meta-analysis by 
Dinh et al. which is stratifying the utility of diagnostic tests in dia-
betic foot [12, 13] . Bone biopsy has a sensitivity of 60%, specificity 
91%, plain X-ray 54% and 68%, MRI 90% and 79%, and radiola-
belled granulocytes scintigraphy 74% and 68%, respectively. The 
authors believe that the best tests for diagnosing osteomyelitis are 
bone probing, bone biopsy, and, among imaging modalities, MRI 
scanning. Similar results were obtained in the meta-analysis by 
Kapoor et al. [13]. Is it correct? Probing exposed bone or its bi-
opsy applies to a somewhat advanced phase of foot ulceration. 
The meta-analysis of Dinh also does not include the role of PET. 
However, other meta-analyses do exist. Butalia et al. believe 
that the clinical data are decisive. An area of ulceration larger than 
2 cm2, blood sedimentation rate above 70 mm/h, positive bone 
biopsy, and positive plain X-ray result are sufficient to diagnose 
bone involvement. In dubious cases, MRI scanning may aid the 
diagnosis [50]. 
Other authors believe that the imaging should be started with 
plain X-ray, particularly if Charcot’s osteoarthropathy is suspected. 
Three-phase bone scintigraphy is diagnostic in the toes and 
forefoot, but not in the hindfoot, CT is of little use, and the extent 
of surgical intervention is best defined by MRI; the gold standard 
of differentiation between osteoarthropathy and bone infection 
is granulocyte scanning, preferably performed at the same time 
as MRI [51]. 
Probably there is no “one best test”, and the existing ones are 
complementary. MRI is the test of choice, but the forthcoming 
years will probably bring technological advances in functional 
modifications and hybrid imaging, redefining existing algorithms. 
Therefore, at present a diagnostic imaging algorithm would 
look as follows: 
— in uncomplicated diabetic foot, plain X-ray as a first choice, MRI 
scanning defining the extent of surgery, radionuclide scanning 
if there are doubts in MRI;
—  in Charcot’s osteoarthropathy: as above + three-phase bone 
scintigraphy or inflammation-agent scintigraphy;
—  vascular assessment should always be performed: Dop-
pler ultrasound possibly with classical angiography or MR 
angiography  for defining the need and extent of angiological 
intervention. 
This algorithm may be modified by the growing role of PET/CT 
and PET/MRI in future. Today its main limitation is the cost of 
PET/CT scanning and its low availability. In the authors’ country 
the cost of diabetic foot PET scanning is not reimbursed by the 
national health insurance system. However, this may change along 
with development of conservative surgery. FDG-PET is a highly 
specific imaging modality for the diagnosis of osteomyelitis in 
diabetic foot and, therefore, should be considered as a useful 
complimentary imaging modality with MRI. In the setting where 
MRI is contraindicated, the high sensitivity and specificity of 
FDG-PET justifies its use after a negative or inconclusive PFR to 
aid an accurate diagnosis [52]. Today health care reimbursement 
systems prefer plain foot amputations, but if indirect costs of 
post operation care, pensions, and socio-economical factors of 
patients post-amputation are taken into consideration the de-
velopment of conservative surgery with its associated imaging 
methods seems to be the future. 
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